DOCSLIB.ORG

2019Finalpricetransparencyforjan1.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2019Finalpricetransparencyforjan1.Pdf DESCRIPTION CHARGE 17 HYDROXYPROGESTER, SER 641 24 HR URINE CHLORIDE 118 24 HR URINE COPPER 289 24 HR. URINE/CITRIC ACID 657 3-D TUMOR LOCAL 5,000 3D W/INTERP&POSTPROC-SAME WRKST 906 3D W/INTRP&POSTPROC-REQ.DIFF.WKST 1,768 A-AUGMENTIN SUSP, 600MG/5ML 19 ABACAVIR SOLN, 20 MG/ML (240ML 4 ABACAVIR TAB, 300MG 57 ABACAVIR/LAMIVUDINE/ZIDOVUDINE 171 ABATACEPT, PER 10 MG, INJ (250MG) 266 ABCIXIMAB INJ, 10MG/5ML 8,332 ABD PARACENTESIS W/IMAGING 2,758 ABD PARACENTESIS W/O IMAGING GUID 1,581 ABD.ACUTE(SUP/ER-DECUB)W/1V CHEST 833 ABDOMEN RETROPERT COM 2,126 ABDOMEN RETROPERT LTD 1,457 ABDOMEN XRAY 1 VIEW 490 ABDOMEN XRAY 2 VIEWS 612 ABDOMEN XRAY 3 OR MORE VIEWS 719 ABDOMEN,COMPLETE 2,125 ABDOMEN,LIMITED 1,689 ABDOMEN-2 VIEWS 609 ABDOMEN-SINGLE AP 616 ABDOMINAL AORTOGRAPHY/RADIOL S&I 4,949 ABG ARTERIAL BLOOD GAS 338 ABLAT.PROBE HIPVAC 50IFS 72290004 2,773 ABLATE ARRHYTHMIA ADD ON-8246 13,801 ABLATION PROBE-CERTUS-LK/LN/PR/SR 7,425 ABLATION, AVN 8,035 ABSORBABLE GELATIN FILM, (10X12.5 7,996 A-C JOINTS BILAT 265 ACCOLADE C DISTAL SPACER 10596715 473 ACCULIF CAGE 6-9X11X34 305006 32,926 ACET REV SHELL 64MM 00700006420 19,395 ACET REV SYS CAGE RT 00713506254 2,831 ACET REV SYSTCROSSLINK00710506236 10,695 ACETAMINOPHEN 120MG SUPP 3 ACETAMINOPHEN 325MG SUPP 4 ACETAMINOPHEN 325MG TAB 0 ACETAMINOPHEN 325MG/10ML ELIX 20 ACETAMINOPHEN 500MG TAB 0 ACETAMINOPHEN 650MG SUPP 3 ACETAMINOPHEN 80MG CHEW TAB 0 ACETAMINOPHEN ASSAY 374 ACETAMINOPHEN ELIX 640MG/20ML 14 ACETAMINOPHEN SUPP 80MG 5 ACETAMINOPHEN SUPP, 650MG 164 ACETAMINOPHEN SUSP, 160MG/5ML 9 ACETAMINOPHEN,@ 10MG,INJ (1000MG) 2 ACETAZOLAMIDE 500MG CAP SEQUEL 24 ACETAZOLAMIDE SOD@ 500MG INJ(500) 282 ACETAZOLAMIDE TAB, 250MG 24 ACETIC ACID IRRIG.SOL,0.25%-500ML 28 ACETIC ACID OTIC SOLN 15ML 227 ACETYCHOLINE INTRAOCULAR, 1% 582 ACETYLCHOLINE RECEPTOR AB 853 ACETYLCYSTEINE SOLN, 20% (10ML) 83 ACETYLCYSTEINE SOLN, 20% (4ML) 85 ACETYLCYSTEINE SOLN,10%(30ML) 65 ACETYLCYSTEINE,@100MG,INJ(6000MG) 21 ACETYLCYSTINE SOL 20% D5W 100ML 24 ACID PHOS (PROSTATIC) 180 ACL GRAFT KNIFE 10MM 232110 1,019 ACL GRAFT KNIVE 9MM 232109 1,019 ACTH 905 ACTIVATED CLOTTING TIME 170 ACTIVATED PROTEIN C RESIS 327 ACTIVE WOUND CARE > 20 CM 735 ACTIVE WOUND CARE/20 CM OR < 1,248 ACULAR OPHTH SOLN 0.5% 780 ACUPUNCTURE-W/O STIM-1ST 15 MIN 50 ACUTE HEPATITIS PANEL 1,114 ACYCLOVIR @ 5MG INJ (500MG/10ML) 1 ACYCLOVIR @ 5MG INJ(1000MG/20ML) 1 ACYCLOVIR @ 5MG INJ(50MG-PED SYR) 0 ACYCLOVIR @ 5MG INJ(5MG-NICU SYR) 1 ACYCLOVIR 5% OINT 15GM 4,519 ACYCLOVIR CAP, 200MG 7 ACYCLOVIR CRM 5%, (5 GM) 4,557 ACYCLOVIR SUSP 200MG/5ML 27 ACYCLOVIR TAB, 800MG 21 ADAPER OFFSET TRIATH 2MM 55705020 6,418 ADAPT STEM OSS 1CM 150494 27,404 ADAPT TRAY HUMER EQUINOXE 3201000 8,976 ADAPTER APEX PIN HOFFMAN 49331020 1,458 ADAPTER OFFSET 4MM 6,418 ADAPTER SMR STD+4 133015274 2,045 ADAPTER STAGE1 HIP NECK 431186 1,432 ADAPTER TUOHY BORST G18813 163 ADAPTOR FEMORAL 5 8,554 ADAPTOR TAPER HUM HEAD 118001 1,148 ADENOSINE,PER 1 MG, INJ (12MG) 6 ADENOSINE,PER 1 MG, INJ (60 MG) 10 ADENOSINE,PER 1 MG, INJ (6MG) 7 ADENOVIRUS 302 ADHESIVE SKIN MASTISOL 2OZ 052306 157 ADL/LIFE SKILLS OCCUPATIONAL THER 255 ADMINISTRATION OF FLU VACCINE 68 ADMINISTRATION-HEP.B VACCINE 102 ADMINISTRATION-PNEUMONIA VACCINE 102 ADRENAL ANTIBODY 283 AEQUALIS REVERSED 9,180 AEQUALIS REVERSED 3MM 8,494 AEROBIC ISOLATE ID 189 AEROSOL TRMT/INITIAL EVAL 340 AEROSOLIZED TREATMENT SUBSEQUENT 209 AFB SMEAR ONLY 125 AGGRENOX CAPSULE, 25MG-200MG 47 ALBENDAZOLE TAB, 200 MG 763 ALBUMIN 25%, PER 50ML, INJ(100ML) 564 ALBUMIN 5%, PER 250ML, INJ(500ML) 354 ALBUMIN INJ, 25% (50ML) 564 ALBUMIN INJ, 5% (250ML) 637 ALBUMIN INJ, 5% (50ML) 167 ALBUMIN, SERUM 116 ALBUTEROL 2MG/5ML SYRUP 4 ALBUTEROL CFC FREE INHALER,90MCG/ 386 ALBUTEROL HFA INHALER, 18 GM 365 ALBUTEROL NEB SOLN, 0.083% (3ML) 2 ALBUTEROL NEB SOLN, 0.5% (20ML) 1 ALBUTEROL NEB SOLN,0.021%(3ML)PED 6 ALBUTEROL NEB SOLN,0.042%(3ML)PED 7 ALBUTEROL NEB SOLN,0.5%(0.5ML) 1 ALBUTEROL SULFATE INHALER, 18GM 132 ALBUTEROL SULFATE PER MG 15 ALCHOL SOL, 70% (480ML) 12 ALCOHOL,BLOOD-ETHANOL ASSAY 252 ALDACTAZINE ORAL SUSP 3 ALDOLASE SERUM 226 ALDOSTERONE PLASMA 959 ALEXIS EXTRACTION SYSTEM GTG17 4,816 ALEXIS ORTHO PROTECT SM/MED HR004 847 ALISKIREN TAB, 150MG 41 ALKALINE PHOS BONE ISO 29498 545 ALKALINE PHOSPHAT ISOENZ 344 ALKALINE PHOSPHATASE 122 ALLERGY TESTING,PERC/DERM,# TESTS 100 ALLOGRAFT ACHILL TENDW/BLCK453042 11,676 ALLOGRAFT BIOADAPT DBM BRIDGE24CC 8,173 ALLOGRAFT BIOREADY DBM5CC DS00105 3,503 ALLOGRAFT BONE PATELLA10MM 443002 21,490 ALLOGRAFT BONEPAT TEND9/10 443012 20,141 ALLOGRAFT BREASTFLEXHD11X20SF2000 30,836 ALLOGRAFT BREASTFLEXHD13X22SF3000 33,483 ALLOGRAFT BREASTFLEXHD13X22SF3300 30,636 ALLOGRAFT BRST KIT 9X15 SF1000 19,017 ALLOGRAFT CANC PLUG 11 FCPD11 2,611 ALLOGRAFT FEM HEMICOND LFT FCA80 67,843 ALLOGRAFT FEMORAL CORT STRUT 25CM 14,960 ALLOGRAFT FIBULA SHAFT 10 CM 4,782 ALLOGRAFT FLEXIGRAFT FROZ FGL 13,830 ALLOGRAFT GRAFIXCORE5X5CM PS12055 15,967 ALLOGRAFT ILIUM 60MM 450910 18,476 ALLOGRAFT ILLUM 2.2CMX55MM 400520 15,636 ALLOGRAFT LATERAL MENISCUS 34,990 ALLOGRAFT MENISCUS LFT FMNLL 26,884 ALLOGRAFT PATELTENDON11/11 443005 20,141 ALLOGRAFT POST TIB 220MM 443016 15,179 ALLOGRAFT REV CORE 14MM 400134 6,867 ALLOGRAFT REV CORE10MM 400130 6,526 ALLOGRAFT STRAVIX 2X4CM PS60005 9,428 ALLOGRAFT STRAVIX 3X6CM PS60008 14,974 ALLOGRAFT TALUS LFT 32647002 37,947 ALLOGRAFT TEND VERSAGRAFT VRG001 7,531 ALLOGRAFT TENDON3-10MMX26 430350 8,845 ALLOGRAFT TISJUVCARTIL00560600011 25,595 ALLOGRAFT TRINITY ELITE 410002 17,689 ALLOGRAFT WEDG25-30MM ILIAC450914 9,097 ALLOGRAFT WEDGE8MM ILIAC CR450913 5,494 ALLOGRAFT WEDGE9MM ILIAC CR450912 5,882 ALLOGRFT GRAFIXPRIME2X3CM PS11023 6,101 ALLOGRFT GRAFIXPRIME3X4CM PS11034 7,487 ALLOGRFT GRAFIXPRIME5X5CM PS11055 15,973 ALLOGRFT PUROS CANC PART1CC 68211 800 ALLOPURINOL TAB, 100MG 2 ALLOWRAP DS 2X2 CM 31022002 6,120 ALLUPURINOL TAB, 300 MG 4 ALPHA FETOPROTEIN SERUM 391 ALPHA I ANTITRYPSIN 316 ALPHA/ANTITRYPSIN PHENOTY 337 ALPHAGAN P 0.15% 738 ALPRAZOLAM 0.25MG TAB 0 ALPRAZOLAM 0.5MG TAB 4 ALPROSTADIL PED INJ, 500MCG/ML 2 ALS I NON-EMERGENCY TRANSPORT 1,538 ALS LEVEL 1 ASSESSMENT ONLY 3,432 ALS LEVEL 1 EMERGENCY TRANSPORT 3,432 ALS LEVEL 2 3,820 ALTAZANAVIR CAP, 150MG 157 ALTAZANAVIR CAP, 200MG 157 ALTEPLASE, PER 1 MG, INJ (1MG/ML) 266 ALTEPLASE, PER 1 MG, INJ (2MG) 491 ALTEPLASE, PER 1 MG,INJ (100 DIL) 560 ALUM HYDROXIDE SUSP, 320 MG/5ML 27 ALUM. AMMONIUM PWD. 255 ALUMINUM 590 AMANTADINE 100MG CAP 12 AMANTADINE SYRUP, 50MG/5ML 8 AMBULANCE SERVICE(BLS)TRANSPORT 943 AMIKACIN SULF@100MG INF(500MG-PB) 17 AMIKACIN SULF@100MG INF(5MG-NICU) 6 AMILORIDE TAB, 5 MG 7 AMINO ACID 5% / DEX 15%, 2000 ML 453 AMINO ACID 5% / DEX 20%, 2000 ML 567 AMINO ACID INJ, 10% (PEDIATRIC) 21 AMINO ACID INJ, 15% (NOVAMINE) 85 AMINO ACID QUANT ON CSF 1,179 AMINO ACID QUANTIT ON URI 401 AMINOCAPROIC ACID 500MG TAB 140 AMINOCAPROIC ACID INJ, 5G/20ML 15 AMINOPHYLLIN @ 250MG INJ (250MG) 23 AMIODARENE 249 AMIODARONE 200MG TAB 3 AMIODARONE HCL @ 30 MG INJ (150) 5 AMIODARONE HCL @ 30 MG INJ (450) 2 AMIODARONE HCL @ 30 MG INJ (900) 4 AMIPICILLIN @500MG INJ(VIAL125MG) 118 AMIPICILLIN @500MG INJ(VIAL250MG) 45 AMIPICILLIN @500MG INJ(VIAL500MG) 25 AMITRIPTYLINE ASSAY 417 AMITRIPTYLINE HCL TAB 50MG 4 AMITRIPTYLINE HCL TAB, 10MG 1 AMITRIPTYLINE HCL TAB, 25MG 2 AMLODIPINE BESYLATE TAB, 2.5MG 9 AMLODIPINE BESYLATE TAB, 5MG 9 AMLODIPINE TAB, 10MG 1 AMMONIA PLASMA 342 AMMONIA SPIRIT, ARROMTIC INH 2 AMNIOCENTESIS 989 AMOXICILLIN & K CLAVANATE 28 AMOXICILLIN 250MG CAP 1 AMOXICILLIN CAP, 500MG 2 AMOXICILLIN SUSP 125MG/5ML (UD) 2 AMOXICILLIN SUSP, 250MG/5ML (UD) 2 AMOXICILLIN SUSP, 400 MG/5ML 3 AMPHOTERICIN B@50MG INJ(50MGVIAL) 258 AMPICILLIN @500MG INJ (1G ADD) 24 AMPICILLIN @500MG INJ (1G VIAL) 25 AMPICILLIN @500MG INJ (2G ADD) 24 AMPICILLIN @500MG INJ (2G VIAL) 23 AMPICILLIN CAP, 250MG 1 AMPICILLIN CAP, 500MG 2 AMPICILLIN SUSP,250MG/5ML (UD) 4 AMYLASE SERUM 170 ANA 313 ANA QUANTITATION 261 ANAEROBIC ISOLATE ID 190 ANBESOL LIQUID (9ML) 27 ANCH SUT HEALIX BR 5.5 3SUT222298 1,860 ANCH SUTSWVLCK5.5X19.1MMAR2323BCC 2,290 ANCHOR CANC HTO 28MM AR1340128 1,506 ANCHOR CANC IBAL HTO26MMAR1340126 1,507 ANCHOR CANCELL HTO 30MM AR1340130 1,507 ANCHOR CANCELL HTO 32MM AR1340132 1,507 ANCHOR CORKSCREW 5.5 AR1927BCT 2,033 ANCHOR CORT HTO 32MM AR1340230 1,506 ANCHOR CORT HTO 38MM AR1340238 1,507 ANCHOR CORT HTO 44MM AR1340244 1,507 ANCHOR GRYPHON PEEK 3.0 223147 2,678 ANCHOR KNOTLESS TITAN MITEK212029 1,913 ANCHOR MINI SUT #0 ORTHO 212038 2,391 ANCHOR PEG SHOULDERGLENOID SZ52MM 9,040 ANCHOR QCKANCHR2MMW2ORTHCRD212035 1,891 ANCHOR QFIX SUR 1.8 251800 2,189 ANCHOR QFIX SUT 2.8 252800 2,189 ANCHOR SUT 4.75X19.1 AR2324PSLC 1,927 ANCHOR SUT BIO4.75X19.1 AR2324BCC 2,290 ANCHOR SUT BIOC 6.25X19.1AR1662BC 2,048 ANCHOR SUT FIBERTAK DBLLD AR36022 2,160 ANCHOR SUT FOOTPRINT 4.5 72202901 2,074 ANCHOR SUT FOOTPRINT 4.5 72203783 2,481 ANCHOR SUT HEALICOIL 4.5 72203378 2,210 ANCHOR SUT HEALICOIL 5.5 72203380 2,299 ANCHOR SUT HEALICOIL 5.5 72203983 2,189 ANCHOR SUT HEALICOIL 5.5 72203984 2,189 ANCHOR SUT HEALIX 5.5 222331 2,105 ANCHOR SUT MENS DARTSHEALTHAR3007 536 ANCHOR SUT MULTIFIX 5.5 72290001 2,189 ANCHOR SUT PEEK 2.9X12.5 AR2923PS 1,985 ANCHOR SUT PEEK 4.75 AR2324PCT 2,481 ANCHOR SUT PEEK 5.5 72203379 2,014 ANCHOR SUT PEEK 5.5X20 AR2323PSL 2,145 ANCHOR SUT PEEK 7X19.5 AR1662PSL7 2,317 ANCHOR SUT PEEK5.5X19.1AR2323PSLC 1,927 ANCHOR SUT RELOAD AR7203 132 ANCHOR SUT SWIVLCK8X19.5AR1662BC8 2,440 ANCHOR SUTURE 2.4X6.5 AR1320BCNF 1,859 ANCHOR SUTURE 2.9X12.5 AR2923BC 2,288 ANCHOR SUTURE 3X14MM AR1934BCF2 1,927 ANCHOR SUTURE BIORAP 72201541 1,643 ANCHOR SUTURE FASTIN#2 222720 2,163 ANCHOR SUTURE FOOTPNT5.5
Load more

Recommended publications
  • Group II/III Metabotropic Glutamate Receptors Exert Endogenous Activity-Dependent Modulation of TRPV1 Receptors on Peripheral Nociceptors
    The Journal of Neuroscience, September 7, 2011 • 31(36):12727–12737 • 12727 Behavioral/Systems/Cognitive Group II/III Metabotropic Glutamate Receptors Exert Endogenous Activity-Dependent Modulation of TRPV1 Receptors on Peripheral Nociceptors Susan M. Carlton, Shengtai Zhou, Rosann Govea, and Junhui Du Department of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, Texas 77555-1069 There is pharmacological evidence that group II and III metabotropic glutamate receptors (mGluRs) function as activity-dependent autoreceptors, inhibiting transmission in supraspinal sites. These receptors are expressed by peripheral nociceptors. We investigated whether mGluRs function as activity-dependent autoreceptors inhibiting pain transmission to the rat CNS, particularly transient recep- tor potential vanilloid 1 (TRPV1)-induced activity. Blocking peripheral mGluR activity by intraplantar injection of antagonists LY341495 [(2S)-2-amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid] (LY) (20, 100 ␮M, group II/III), APICA [(RS)-1- amino-5-phosphonoindan-1-carboxylic acid] (100 ␮M, group II), or UBP1112 (␣-methyl-3-methyl-4-phosphonophenylglycine) (30 ␮M, groupIII)increasedcapsaicin(CAP)-inducednociceptivebehaviorsandnociceptoractivity.Incontrast,groupIIagonistAPDC[(2R,4R)- 4-aminopyrrolidine-2,4-dicarboxylate] (0.1 ␮M) or group III agonist L-(ϩ)-2-amino-4-phosphonobutyric acid (L-AP-4) (10 ␮M) blocked the LY-induced increase. Ca 2ϩ imaging in dorsal root ganglion (DRG) cells confirmed LY enhanced CAP-induced Ca 2ϩ mobilization, which was blocked by APDC and L-AP-4. We hypothesized that excess glutamate (GLU) released by high intensity and/or prolonged stimulation endogenously activated group II/III, dampening nociceptor activation. In support of this, intraplantar GLU ϩ LY produced heat hyperalgesia, and exogenous GLU ϩ LY applied to nociceptors produced enhanced nociceptor activity and thermal sensitization.
    [Show full text]
  • Brooks Rehabilitation Charge Master 12.28.18
    Brooks Rehabilitation Charge Master 12.28.18 Mnemonic Name Charge Category Category Description Amount 200020 4 Rehab/Private 118 Rehabilitation - Room and Board- Private (Medical or General) $1,400.00 200021 4 Rehab/Semi Private 118 Rehabilitation - Room and Board- Private (Medical or General) $1,400.00 210020 2 Rehab/Private 118 Rehabilitation - Room and Board- Private (Medical or General) $1,400.00 210050 2 Rehab Peds/Private 118 Rehabilitation - Room and Board- Private (Medical or General) $1,400.00 220020 3 Rehab/Private 118 Rehabilitation - Room and Board- Private (Medical or General) $1,400.00 230020 2 E Rehab/Private 118 Rehabilitation - Room and Board- Private (Medical or General) $1,400.00 239020 3 East Rehab 118 Rehabilitation - Room and Board- Private (Medical or General) $1,400.00 220021 3 Rehab/Semi Private 128 Rehabilitation - Room and Board-Semi-Private Two Bed (Medical or General) $1,400.00 219999 LOA Charge 180 General Leave of Absence $- 149900 Legal Billing 229 Other Special Charges $- 208031 Specialty Bed 229 Other Special Charges $- 218031 Specialty Bed 229 Other Special Charges $- 228031 Specialty Bed 229 Other Special Charges $- 238031 Specialty Bed 229 Other Special Charges $- 239031 Specialty Bed 229 Other Special Charges $- 309369 Misc Charges 229 Other Special Charges $- NONTAX Non Tax Client Rev 229 Other Special Charges $- TAXSUP Taxable Supplies 229 Other Special Charges $- 147557 Physical Perf Test/Measure FCE 240 General - All Inclusive Ancillary $135.00 149712 Neuro Program 1/2 Day 240 General - All Inclusive
    [Show full text]
  • Involvement of Metabotropic Glutamate Receptor 5 in Ethanol
    Life Sciences 233 (2019) 116729 Contents lists available at ScienceDirect Life Sciences journal homepage: www.elsevier.com/locate/lifescie Involvement of metabotropic glutamate receptor 5 in ethanol regulation of NMDA receptor activity in rat substantia gelatinosa neurons T ⁎ Chih-Chia Laia,b, Jhih-Wei Hsuc, Yi-Shan Chengb, Hsun-Hsun Linc,d, a Department of Pharmacology, School of Medicine, Tzu Chi University, Hualien, Taiwan 970 b Master and Ph.D. Programs in Pharmacology and Toxicology, School of Medicine, Tzu Chi University, Hualien, Taiwan 970 c Master Program in Medical Physiology, School of Medicine, Tzu Chi University, Hualien, Taiwan 970 d Department of Physiology, School of Medicine, Tzu Chi University, Hualien, Taiwan 970 ARTICLE INFO ABSTRACT Keywords: Aims: Glutamatergic receptors are important targets of ethanol. Intake of ethanol may produce analgesic effects. Ethanol The present study examined the effects of ethanol on the activity of ionotropic glutamate receptors in spinal cord Tolerance substantia gelatinosa (SG) neurons, critical neurons involved in nociceptive transmission. Substantia gelatinosa neurons Main methods: Whole-cell recordings were made from SG neurons of the lumbar spinal cord slices from 15 to 20- NMDA day-old rats. Ethanol and glutamate receptor agonists or antagonists were applied by superfusion. PKC Key finding: Ethanol (50 and 100 mM) applied by superfusion for 5 min dose-dependently decreased the am- mGluR5 plitude of evoked excitatory postsynaptic potential in SG neurons. Superfusion of ethanol (100 mM) for 15 min consistently inhibited NMDA- or AMPA-induced depolarizations in SG neurons. Ethanol (100 mM) also inhibited the depolarizations induced by glutamate. However, ethanol inhibition of glutamate-induced responses sig- nificantly decreased at 10–15 min following continuous superfusion, suggesting the development of acute tol- erance to the inhibition during prolonged exposure.
    [Show full text]
  • Product Update Price List Winter 2014 / Spring 2015 (£)
    Product update Price list winter 2014 / Spring 2015 (£) Say to affordable and trusted life science tools! • Agonists & antagonists • Fluorescent tools • Dyes & stains • Activators & inhibitors • Peptides & proteins • Antibodies hellobio•com Contents G protein coupled receptors 3 Glutamate 3 Group I (mGlu1, mGlu5) receptors 3 Group II (mGlu2, mGlu3) receptors 3 Group I & II receptors 3 Group III (mGlu4, mGlu6, mGlu7, mGlu8) receptors 4 mGlu – non-selective 4 GABAB 4 Adrenoceptors 4 Other receptors 5 Ligand Gated ion channels 5 Ionotropic glutamate receptors 5 NMDA 5 AMPA 6 Kainate 7 Glutamate – non-selective 7 GABAA 7 Voltage-gated ion channels 8 Calcium Channels 8 Potassium Channels 9 Sodium Channels 10 TRP 11 Other Ion channels 12 Transporters 12 GABA 12 Glutamate 12 Other 12 Enzymes 13 Kinase 13 Phosphatase 14 Hydrolase 14 Synthase 14 Other 14 Signaling pathways & processes 15 Proteins 15 Dyes & stains 15 G protein coupled receptors Cat no. Product name Overview Purity Pack sizes and prices Glutamate: Group I (mGlu1, mGlu5) receptors Agonists & activators HB0048 (S)-3-Hydroxyphenylglycine mGlu1 agonist >99% 10mg £112 50mg £447 HB0193 CHPG Sodium salt Water soluble, selective mGlu5 agonist >99% 10mg £59 50mg £237 HB0026 (R,S)-3,5-DHPG Selective mGlu1 / mGlu5 agonist >99% 10mg £70 50mg £282 HB0045 (S)-3,5-DHPG Selective group I mGlu receptor agonist >98% 1mg £42 5mg £83 10mg £124 HB0589 S-Sulfo-L-cysteine sodium salt mGlu1α / mGlu5a agonist 10mg £95 50mg £381 Antagonists HB0049 (S)-4-Carboxyphenylglycine Competitive, selective group 1
    [Show full text]
  • The Origin and Neuronal Function of in Vivo Nonsynaptic Glutamate
    The Journal of Neuroscience, October 15, 2002, 22(20):9134–9141 The Origin and Neuronal Function of In Vivo Nonsynaptic Glutamate David A. Baker, Zheng-Xiong Xi, Hui Shen, Chad J. Swanson, and Peter W. Kalivas Department of Physiology and Neuroscience, Medical University of South Carolina, Charleston, South Carolina 29425 Basal extracellular glutamate sampled in vivo is present in Infusion of the mGluR2/3 antagonist (RS)-1-amino-5- micromolar concentrations in the extracellular space outside phosphonoindan-1-carboxylic acid (APICA) increased extracel- the synaptic cleft, and neither the origin nor the function of this lular glutamate levels, and previous blockade of the antiporter glutamate is known. This report reveals that blockade of gluta- prevented the APICA-induced rise in extracellular glutamate. mate release from the cystine–glutamate antiporter produced a This suggests that glutamate released from the antiporter is a significant decrease (60%) in extrasynaptic glutamate levels in source of endogenous tone on mGluR2/3. Blockade of the the rat striatum, whereas blockade of voltage-dependent Na ϩ antiporter also produced an increase in extracellular dopamine and Ca 2ϩ channels produced relatively minimal changes (0– that was reversed by infusing the mGluR2/3 agonist (2R,4R)-4- 30%). This indicates that the primary origin of in vivo extrasyn- aminopyrrolidine-2,4-dicarboxlylate, indicating that antiporter- aptic glutamate in the striatum arises from nonvesicular gluta- derived glutamate can modulate dopamine transmission via mate
    [Show full text]
  • Screening for New Psychoactive Substances (NPS) Without Reference Standards on High Resolution Mass Spectrometers (HR-MS)
    UNIVERSIDADE DE LISBOA FACULDADE DE CIÊNCIAS DEPARTAMENTO DE QUÍMICA E BIOQUÍMICA Screening for New Psychoactive Substances (NPS) without reference standards on High Resolution Mass Spectrometers (HR-MS) Maria Estevão Fidalgo von Cüpper Mestrado em Química Especialização em Química Dissertação orientada por: Professor Dr. Med. Kristian Linnet Dra. Helena Galla Gaspar 2019 “We must have perseverance and above all confidence in ourselves. We must be- lieve that we are gifted for something and that this thing must be attained.” Marie Curie ii ACKNOWLEDGMENTS This master’s thesis represents the culmination of an important stage in my academic life. Thanks to the Erasmus Traineeship Programme, I had the opportunity to take two semesters abroad and venture into the world of forensics, a field that I have always been passionate about. The project was carried out at the Sec- tion of Forensic Chemistry at the Department of Forensic Medicine, University of Copenhagen, Denmark. First of all, I would like to thank Prof. Dr. Med. Kristian Linnet, for giving me the possibility to do this research within the Forensic Chemistry field at the Institute. I would like to express my sincere gratitude to Dr. Petur Dalsgaard, my external supervisor who intro- duced me to the world of New Psychoactive Substances (NPS) and high-resolution mass spectrometry, for his willingness to offer a stimulating environment, continuous support in the development of my thesis, his patience, motivation, immense knowledge, and for providing me with practical tips. I am very grateful to my internal supervisor Dr. Helena Gaspar, who initially guided my enthusiasm to work with NPS.
    [Show full text]
  • Development and Characterization of Novel Allosteric Modulators Acting on Metabotropic Glutamate Receptors 2 and 3
    DEVELOPMENT AND CHARACTERIZATION OF NOVEL ALLOSTERIC MODULATORS ACTING ON METABOTROPIC GLUTAMATE RECEPTORS 2 AND 3 By Cody James Wenthur Dissertation Submitted to the Faculty of the Graduate School of Vanderbilt University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in PHARMACOLOGY August, 2015 Nashville, Tennessee Approved: Professor Craig W. Lindsley Professor P. Jeffrey Conn Professor Randy D. Blakely Professor Aaron B. Bowman Professor Joey V. Barnett To my beloved wife, Brielle, the author of my happiness and To the untested truths, out beyond the ragged frontier ii ACKNOWLEDGEMENTS The following work was generously supported by financial assistance from the Howard Hughes Medical Institute / Vanderbilt University Medical Center Certificate Program in Molecular Medicine, the NIGMS Vanderbilt Pre-Doctoral Pharmacology Training Program, NCATS funds awarded through the Vanderbilt Institute for Clinical and Translational Research, the NIH Clinical Research Loan Repayment Program, and the NIH Molecular Libraries Program. These visionary awards enable scientific studies at the boundaries between disciplines, emphasize the importance of applied science, and champion the development of the next generation of translational researchers. It is no overstatement to say that without such incredible backing, this manuscript would never have come to fruition. Likewise, the continuous guidance and assistance of my committee members was essential. The insights and suggestions of Drs. Randy Blakely, Aaron Bowman, and Joey Barnett, along with their unwavering commitment to helping me pursue my career and research goals, were integral to the success of the project. The current and former chairs of my committee, Drs. Jeff Conn and Scott Daniels, respectively, have both gone far beyond the simple requirements of their positions, providing me with access to their labs, equipment, and expertise – I will always be grateful for the opportunity to have learned from them.
    [Show full text]
  • Product Update Price List Winter 2014 / Spring 2015 (€)
    Product update Price list Winter 2014 / Spring 2015 (€) Say to affordable and trusted life science tools! • Agonists & antagonists • Fluorescent tools • Dyes & stains • Activators & inhibitors • Peptides & proteins • Antibodies hellobio•com Contents G protein coupled receptors 3 Glutamate 3 Group I (mGlu1, mGlu5) receptors 3 Group II (mGlu2, mGlu3) receptors 3 Group I & II receptors 3 Group III (mGlu4, mGlu6, mGlu7, mGlu8) receptors 4 mGlu – non-selective 4 GABAB 4 Adrenoceptors 4 Other receptors 5 Ligand Gated ion channels 5 Ionotropic glutamate receptors 5 NMDA 5 AMPA 6 Kainate 7 Glutamate – non-selective 7 GABAA 7 Voltage-gated ion channels 8 Calcium Channels 8 Potassium Channels 9 Sodium Channels 10 TRP 11 Other Ion channels 12 Transporters 12 GABA 12 Glutamate 12 Other 12 Enzymes 13 Kinase 13 Phosphatase 14 Hydrolase 14 Synthase 14 Other 14 Signaling pathways & processes 15 Proteins 15 Dyes & stains 15 G protein coupled receptors Cat no. Product name Overview Purity Pack sizes and prices Glutamate: Group I (mGlu1, mGlu5) receptors Agonists & activators HB0048 (S)-3-Hydroxyphenylglycine mGlu1 agonist >99% 10mg € 162 50mg € 648 HB0193 CHPG Sodium salt Water soluble, selective mGlu5 agonist >99% 10mg € 86 50mg € 344 HB0026 (R,S)-3,5-DHPG Selective mGlu1 / mGlu5 agonist >99% 10mg € 102 50mg € 409 HB0045 (S)-3,5-DHPG Selective group I mGlu receptor agonist >98% 1mg € 61 5mg € 120 10mg € 180 HB0589 S-Sulfo-L-cysteine sodium salt mGlu1α / mGlu5a agonist 10mg € 138 50mg € 552 Antagonists HB0049 (S)-4-Carboxyphenylglycine Competitive, selective
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0184806 A1 Barlow Et Al
    US 20100184806A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0184806 A1 Barlow et al. (43) Pub. Date: Jul. 22, 2010 (54) MODULATION OF NEUROGENESIS BY PPAR (60) Provisional application No. 60/826,206, filed on Sep. AGENTS 19, 2006. (75) Inventors: Carrolee Barlow, Del Mar, CA (US); Todd Carter, San Diego, CA Publication Classification (US); Andrew Morse, San Diego, (51) Int. Cl. CA (US); Kai Treuner, San Diego, A6II 3/4433 (2006.01) CA (US); Kym Lorrain, San A6II 3/4439 (2006.01) Diego, CA (US) A6IP 25/00 (2006.01) A6IP 25/28 (2006.01) Correspondence Address: A6IP 25/18 (2006.01) SUGHRUE MION, PLLC A6IP 25/22 (2006.01) 2100 PENNSYLVANIA AVENUE, N.W., SUITE 8OO (52) U.S. Cl. ......................................... 514/337; 514/342 WASHINGTON, DC 20037 (US) (57) ABSTRACT (73) Assignee: BrainCells, Inc., San Diego, CA (US) The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system (21) Appl. No.: 12/690,915 including by stimulating or increasing neurogenesis, neuro proliferation, and/or neurodifferentiation. The disclosure (22) Filed: Jan. 20, 2010 includes compositions and methods based on use of a peroxi some proliferator-activated receptor (PPAR) agent, option Related U.S. Application Data ally in combination with one or more neurogenic agents, to (63) Continuation-in-part of application No. 1 1/857,221, stimulate or increase a neurogenic response and/or to treat a filed on Sep. 18, 2007. nervous system disease or disorder. Patent Application Publication Jul. 22, 2010 Sheet 1 of 9 US 2010/O184806 A1 Figure 1: Human Neurogenesis Assay Ciprofibrate Neuronal Differentiation (TUJ1) 100 8090 Ciprofibrates 10-8.5 10-8.0 10-7.5 10-7.0 10-6.5 10-6.0 10-5.5 10-5.0 10-4.5 Conc(M) Patent Application Publication Jul.
    [Show full text]
  • King's Research Portal
    King’s Research Portal DOI: 10.1515/pac-2017-0605 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA): Abbate, V., Schwenk, M., Presley, B., & Uchiyama, N. (2018). The ongoing challenge of novel psychoactive drugs of abuse. Part I. Synthetic cannabinoids (IUPAC Technical Report). PURE AND APPLIED CHEMISTRY, 90(8). https://doi.org/10.1515/pac-2017-0605 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • Tocris製品30％Offキャンペーン価格表（2021/7/5～2021/8/31）
    TOCRIS製品30％OFFキャンペーン価格表（2021/7/5～2021/8/31） （メーカーコード順） 希望納⼊価格 キャンペーン価格 コードNo.メーカーコード 英名 容量 (円） (円） 537-31171 0101/100 DL-2-Amino-4-phosphonobutyric Acid [DL-AP4] 100mg 24,000 16,800 - 0102/10 D(-)-2-Amino-4-phosphonobutyric Acid [D-AP4] 10mg 52,000 36,400 - 0102/50 D(-)-2-Amino-4-phosphonobutyric Acid [D-AP4] 50mg 222,000 155,400 - 0103/1 L(+)-2-Amino-4-phosphonobutyric Acid [L-AP4] 1mg 18,000 12,600 531-26804 0103/10 L(+)-2-Amino-4-phosphonobutyric Acid [L-AP4] 10mg 46,000 32,200 533-26803 0103/50 L(+)-2-Amino-4-phosphonobutyric Acid [L-AP4] 50mg 203,000 142,100 - 0104/10 DL-AP7 10mg 30,000 21,000 - 0104/50 DL-AP7 50mg 120,000 84,000 - 0105/10 DL-AP5 10mg 20,000 14,000 530-57943 0105/50 DL-AP5 50mg 81,000 56,700 - 0106/1 D-AP5 1mg 15,000 10,500 531-26843 0106/10 D-AP5 10mg 39,000 27,300 535-26846 0106/100 D-AP5 100mg 235,000 164,500 539-26844 0106/50 D-AP5 50mg 174,000 121,800 - 0107/10 L-AP5 10mg 54,000 37,800 - 0107/50 L-AP5 50mg 235,000 164,500 514-20993 0109/10 (-)-Bicuculline methobromide 10mg 28,000 19,600 518-20991 0109/50 (-)-Bicuculline methobromide 50mg 126,000 88,200 - 0111/1 Dihydrokainic acid 1mg 17,000 11,900 - 0111/10 Dihydrokainic acid 10mg 42,000 29,400 - 0111/50 Dihydrokainic acid 50mg 189,000 132,300 532-28291 0112/50 gamma-D-Glutamylglycine 50mg 38,000 26,600 539-26861 0114/50 N-Methyl-D-aspartic Acid [NMDA] 50mg 24,000 16,800 535-26863 0114/500 N-Methyl-D-aspartic Acid [NMDA] 500mg 100,000 70,000 533-31151 0125/100 DL-AP3 100mg 30,000 21,000 512-21011 0130/50 (+)-Bicuculline 50mg 47,000 32,900 535-57954 0131/10 (-)-Bicuculline
    [Show full text]
  • Metabotropic Glutamate Receptors Molecular Pharmacology
    Tocris Scientific Review Series Tocri-lu-2945 Metabotropic Glutamate Receptors Molecular Pharmacology Francine C Acher Introduction Laboratoire de Chimie et Biochimie Pharmacologiques et Glutamate is the major excitatory neurotransmitter in the brain. It Toxicologiques, UMR8601-CNRS, Université René Descartes- is released from presynaptic vesicles and activates postsynaptic Paris V, 45 rue des Saints-Pères, 75270 Paris Cedex 06, France. ligand-gated ion channel receptors (NMDA, AMPA and kainate E-mail: [email protected] receptors) to secure fast synaptic transmission.1 Glutamate also activates metabotropic glutamate (mGlu) receptors which Francine C Acher is currently a CNRS Research Director within modulate its release and postsynaptic response as well as the the Biomedical Institute of University Paris-V (France). Her activity of other synapses.2,3 Glutamate has been shown to be research focuses on structure/function studies and drug involved in many neuropathologies such as anxiety, pain, discovery using chemical tools (synthetic chemistry, molecular ischemia, Parkinson’s disease, epilepsy and schizophrenia. modeling), molecular biology and pharmacology within Thus, because of their modulating properties, mGlu receptors interdisciplinary collaborations. are recognized as promising therapeutic targets.3,4 It is expected that drugs acting at mGlu receptors will regulate the glutamatergic system without affecting the normal synaptic transmission. mGlu receptors are G-protein coupled receptors (GPCRs). Eight subtypes have been
    [Show full text]